Marco Boorsma, Forbion

With a ros­ter of gene ther­a­py vets, For­bion makes a bet on 'rel­a­tive­ly emp­ty space' of vec­tor­ized an­ti­bod­ies

The fu­ture waves of gene ther­a­py could look quite dif­fer­ent from the gene re­place­ment of­fer­ings cur­rent­ly on the mar­ket, For­bion reck­ons.

It’s the key idea be­hind Vec­to­rY, a start­up seed­ed by the Eu­ro­pean VC firm that’s out to de­vel­op vec­tor­ized an­ti­bod­ies for mus­cu­lar and neu­rode­gen­er­a­tive dis­or­ders.

Voy­ager Ther­a­peu­tics, which briefly pushed the tech­nol­o­gy to the lime­light with its short-lived Ab­b­Vie col­lab­o­ra­tion, is among the “sev­er­al oth­er com­pa­nies work­ing on it too, but def­i­nite­ly it’s a pret­ty rel­a­tive­ly emp­ty space,” said Mar­co Boors­ma — a gen­er­al part­ner at For­bion who’s step­ping in as in­ter­im CEO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.